Phase III, Open Label Randomized Comparative Clinical Trial of Oral Posaconazole Three Times Per Day versus Weekly High Dose Amphotericin B Lipid Complex (ABLC) for The Prevention of Invasive Fungal Infections In Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant.

Trial Profile

Phase III, Open Label Randomized Comparative Clinical Trial of Oral Posaconazole Three Times Per Day versus Weekly High Dose Amphotericin B Lipid Complex (ABLC) for The Prevention of Invasive Fungal Infections In Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2009

At a glance

  • Drugs Amphotericin B liposomal; Posaconazole
  • Indications Mycoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting ,as reported by M.D. Anderson Cancer Center record.
    • 15 Apr 2009 Enzon Pharmaceuticals added as trial sponsor and lead trial centre as reported by M.D. Anderson Cancer Center.
    • 03 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top